Dana Investment Advisors Inc. Has $1.61 Million Stock Position in Humana Inc. (NYSE:HUM)

Dana Investment Advisors Inc. lessened its holdings in shares of Humana Inc. (NYSE:HUM) by 10.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 6,338 shares of the insurance provider’s stock after selling 775 shares during the period. Dana Investment Advisors Inc.’s holdings in Humana were worth $1,608,000 as of its most recent filing with the SEC.

A number of other hedge funds also recently modified their holdings of HUM. FMR LLC lifted its holdings in shares of Humana by 23.4% during the third quarter. FMR LLC now owns 3,388,859 shares of the insurance provider’s stock worth $1,073,387,000 after purchasing an additional 643,291 shares during the period. Thrivent Financial for Lutherans raised its stake in Humana by 55.6% during the third quarter. Thrivent Financial for Lutherans now owns 600,317 shares of the insurance provider’s stock worth $190,145,000 after buying an additional 214,535 shares during the last quarter. Retirement Systems of Alabama raised its stake in Humana by 735.9% during the fourth quarter. Retirement Systems of Alabama now owns 219,002 shares of the insurance provider’s stock worth $55,563,000 after buying an additional 192,801 shares during the last quarter. Pzena Investment Management LLC raised its stake in Humana by 8.1% during the third quarter. Pzena Investment Management LLC now owns 2,506,250 shares of the insurance provider’s stock worth $793,830,000 after buying an additional 187,903 shares during the last quarter. Finally, Worldquant Millennium Advisors LLC bought a new position in Humana during the third quarter worth $50,102,000. Institutional investors and hedge funds own 92.38% of the company’s stock.

Humana Stock Down 2.2 %

Humana stock opened at $259.86 on Friday. Humana Inc. has a fifty-two week low of $213.31 and a fifty-two week high of $406.46. The stock has a market cap of $31.35 billion, a PE ratio of 26.12, a price-to-earnings-growth ratio of 2.05 and a beta of 0.57. The firm’s 50-day simple moving average is $271.80 and its 200 day simple moving average is $283.63. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.76 and a current ratio of 1.76.

Humana (NYSE:HUM) last released its quarterly earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) earnings per share for the quarter, topping the consensus estimate of ($2.26) by $0.10. Humana had a net margin of 1.02% and a return on equity of 11.70%. Research analysts predict that Humana Inc. will post 16.47 EPS for the current fiscal year.

Humana Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, April 25th. Shareholders of record on Friday, March 28th will be paid a $0.885 dividend. This represents a $3.54 dividend on an annualized basis and a yield of 1.36%. The ex-dividend date of this dividend is Friday, March 28th. Humana’s payout ratio is 35.58%.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on the stock. JPMorgan Chase & Co. lowered their target price on shares of Humana from $257.00 to $256.00 and set a “neutral” rating for the company in a research note on Tuesday, February 18th. Morgan Stanley decreased their price target on shares of Humana from $301.00 to $285.00 and set an “equal weight” rating for the company in a research note on Wednesday, February 12th. Truist Financial lifted their price target on shares of Humana from $260.00 to $290.00 and gave the company a “hold” rating in a research note on Monday, January 6th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $283.00 price target on shares of Humana in a research note on Wednesday, February 12th. Finally, Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $290.00 price target on shares of Humana in a research note on Wednesday, February 12th. Twenty equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $285.68.

Insider Buying and Selling at Humana

In other Humana news, insider Timothy S. Huval sold 3,703 shares of the business’s stock in a transaction dated Tuesday, December 31st. The shares were sold at an average price of $256.26, for a total value of $948,930.78. Following the transaction, the insider now directly owns 8,181 shares in the company, valued at $2,096,463.06. The trade was a 31.16 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 0.32% of the company’s stock.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.